Hot Deals:
adtech 29.10 (0.34 %) agarwal bolts 1,200.00 (0.00 %) amol minechem 525.00 (1.94 %) anand i-power 20.00 anglo french drugs 745.00 (-0.67 %) apl metals 40.00 (-4.78 %) arkfin investments 50.00 arohan 125.00 (3.31 %) assam carbon 200.00 (2.56 %) atlas copco 10,000.00 (1.01 %) auckland international 129.00 (-0.77 %) av thomas 16,750.00 (1.18 %) axles 220.00 (-2.22 %) balmer lawrie 199.00 (1.02 %) bharat hotels 200.00 (-2.44 %) bima mandi 700.00 bira 600.00 (1.69 %) boat 900.00 (1.12 %) c & s electric 550.00 (0.92 %) cable corporation 12.10 (0.83 %) capgemini 11,300.00 (1.70 %) care health 170.00 (-0.58 %) carrier aircon 290.00 (-3.33 %) cial 189.00 (1.07 %) csfbl 380.00 (2.70 %) csk 160.00 (0.00 %) dalmia refract 145.00 (-2.03 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 425.00 (2.66 %) electronica plastic 4,100.00 (-0.24 %) elgi ultra 400.00 elofic 2,100.00 (2.44 %) esl steel 23.00 (0.44 %) fincare business 45.50 (1.11 %) fincare sfbl 136.00 (-2.86 %) finopaytech 139.00 (-0.71 %) flipkart india 231,001.00 (0.00 %) frick india 7,300.00 (2.82 %) gkn driveline 1,250.00 (4.17 %) go digit general insurance ltd 354.00 (1.14 %) godavari bio 71.00 (1.43 %) hdb financial 640.00 (-1.54 %) hdfc ergo 370.00 (1.70 %) hdfc securities 10,700.00 (-0.93 %) hella india 810.00 (1.25 %) hero fincorp 1,180.00 (1.72 %) hexaware 600.00 (1.69 %) hicks 1,450.00 (2.11 %) hira ferro 150.00 (0.67 %) honeywell electrical 3,600.00 (-0.28 %) ikf finance 221.00 (0.45 %) incred financial 100.00 india carbon 900.00 (-1.10 %) india exposition 135.00 (-0.74 %) indian potash 1,300.00 (-0.38 %) indo alusys 25.75 (-0.96 %) indofil 635.00 (-0.78 %) infinite computer 405.00 (1.25 %) inkel 12.00 (-1.64 %) ixigo 95.00 (-1.04 %) jana small finance bank 75.00 kel 510.00 (-1.92 %) kial 97.00 (1.04 %) klm axiva 16.20 (0.62 %) kurlon limited 490.00 (-2.00 %) lava 92.00 (-1.08 %) mahindra rural mrhfl 100.00 manipal housing 72.50 (0.69 %) manjushree technopack 1,010.00 (1.00 %) martin & harris 1,125.00 (4.17 %) merino 3,030.00 (-2.26 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 410.00 (1.23 %) mobikwik 315.00 (-1.56 %) mohan meakin 1,640.00 (0.92 %) mohfl 9.30 (3.33 %) msei 0.86 (-2.27 %) msil 41.00 (-8.89 %) nayara energy 250.00 (-1.96 %) nayara energy ncd 255.00 (-1.92 %) ncdex 275.00 ncl buildtek 200.00 (2.56 %) ncl holdings 65.00 (8.33 %) nsdl 700.00 nse 3,400.00 (1.49 %) orbis financial 117.00 (1.74 %) oswal minerals 60.10 (-1.48 %) otis 4,000.00 (2.56 %) oyo 73.00 (1.39 %) panasonic appliances 202.00 (1.00 %) panasonic avc 29.00 (-0.34 %) paymate india 360.00 (2.86 %) pharmeasy 9.00 (-3.23 %) philips domestic 540.00 (2.86 %) philips india 875.00 (2.94 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 320.00 (1.59 %) rapido 16,650.00 (0.03 %) rasoi 31,500.00 (0.32 %) resins plastics 415.00 (-1.89 %) ring plus aqua 405.00 (0.25 %) rrl 1,275.00 (2.00 %) sab miller 365.00 (-3.69 %) sbi amc 1,075.00 (1.90 %) sbi general insurance 569.00 scottish assam 446.00 (0.68 %) shriram life 261.00 (0.38 %) sigachi laboratories 39.00 (-2.74 %) signify 1,510.00 (0.67 %) smile microfinance 54.00 (3.85 %) sportskeeda 3,303.00 sterlite power 520.00 (1.96 %) studds 830.00 (-0.60 %) svsml 333.00 (-4.86 %) swiggy 361.00 (0.28 %) t stanes 770.00 (2.67 %) tata capital 480.00 (2.13 %) tata tech 940.00 (1.62 %) teesta agro 77.00 (-6.21 %) trl krosaki 1,200.00 (1.69 %) utkarsh coreinvest 190.00 (2.70 %) vadilal dairy 10.00 vikram solar 350.00 (2.94 %) waree energies 900.00 (12.50 %) zylog 0.01 (-0.99 %)
×

Arch Pharmalabs Share Price

Company Name
Arch PharmaLabs Limited
Scrip Name
Arch Pharmalabs
Last Traded Price
90.10
+ 0.11 %
Sector
Other
PAN No.
AACCM0306Q
Face Value
10
No. of Outstanding Shares
151,923,000
EPS
3.864
PE ratio
23.318
Market Capitalization
1,368.83 Crore
Book value
39.936
P/BV
2.2561
ISIN No.
INE182F01017
Available on
nsdlcdsl
ROFR Require
No

Arch Pharma Labs Limited Delisted Share - Company Overview

ARCH PHARMA LABS LIMITED is a pharmaceutical company aligned across two business verticals viz. Products and Services. The Products business of the company comprises the manufacture and sale of Active Pharmaceutical Ingredients (“API”) and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. In services business of the company includes Contract Research and Manufacturing Services (“CRAMS”). Currently, the company owns and manages 9 multipurpose manufacturing facilities.

The Company has a diversified portfolio and offers more than 120 products ( over 65 APIs and over 55 Intermediates) across various therapeutic segments, such as lipid-lowering agents, oncology, anti-platelet agents, anti-asthmatic,anti-retroviral, anti-anginal, calcium channel blockers, anti-hypertensive,anti-histamine, anti-diabetic, anti-protozoal, anti-fungal, anti-emetic, proton pump inhibitors, expectorant, anti-depressant, decongestant, anti-convulsant, psychostimulant, hypnotic, anti-parkinsonian, anti-gout, analgesic, and others.

The Company provides contract manufacturing, custom synthesis, and contract research services comprising route selection, process development, optimization, analytical development, stability studies, safety studies, scale-up to technology transfer, clinical-trial manufacturing, and commercial manufacture.

Arch Pharmalabs Limited has technology tie-ups with Codexis (USA), Orochem Technologies (USA), and DSM (Netherlands). The use of these technologies helps the company to implement various green chemistry initiatives which are not only environmentally friendly but also reduce production costs.

Incorporation Details of Arch Pharma Labs Limited

CIN of Arch Pharma Labs

U24231MH1993PLC150891

Registration Date of Arch Pharma Labs

02 April 1993

Category/Sub-category of Arch Pharma Labs

Company Limited by Shares

Arch Pharma Labs Registered office address and contact details

3rd Floor, Titanic Building, Chandivali Farm Road,

Nr. HDFC Bank, Andheri (East), Mumbai - 400072.

Tel. : +91-22-4287 1210

Arch Pharma Labs Registrar and Transfer Agent address and contact details

Link Intime India Private Limited

C-101, 247 Park, L.B.S Marg,

Vikhroli (West), Mumbai - 400083,

Tel: 022-25946970

Principal Business Activities of Arch Pharma Labs Limited

Name and Description of main products/services

NIC Code of the product/service

% to total turnover of the Company

Pharmaceutical products

21002 & 21005

100%

Board of Directors of Arch Pharma Labs Limited

Mr. Ajit Kamath (Chairman & Managing Director)

Mr. Rajendra Kaimal (Executive Director & CFO)

Mr. Ashish Ujagare (Executive Director)

Dr. Sunil Pitroda (Independent Director)

Particulars of Subsidiaries and Associates Companies of Arch Pharma Labs 

Name of the Company

Subsidiary/Associate

% of shares held

Arch Life SciencesLimited

Subsidiary

58.46%

Arch FinechemicalsLimited

Subsidiary

88.95%

Arch Pharmalabs FZLLC

Subsidiary

100.00%

Kobo Biotech Limited

Associate

44.95%

Shareholding Pattern of Arch Pharma Labs Limited (As of 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

Arch Impex Private Limited

5,54,05,664

36.47%

2

Arch PharmachemLimited

2,11,81,000

13.94%

3

ArchAgroIndustriesPrivate Limited

61,54,754

4.05%

4

AMR InvestmentsPrivate Limited

19,76,681

1.30%

5

Arch Herbals Private limited

62,42,076

4.11%

6

Public Shareholding

6,09,62,901

40.12%

 

Total

15,19,23,076

100.00%

Industry Outlook

The Global pharmaceutical industry is valued at around US$ 1250 billion. The US market alone accounts for 48% of the market. India and China each stand at US$ 53 billion and US$ 190 billion respectively. India is the largest provider of generic drugs and is fulfilling around 20% of the global demand.

In the Active Pharmaceutical Ingredients (API) Industry, if we see the units approved by USFDA, US leads with 28% approval rating, Europe with 26%, and India & China with 18% and 13% respectively. It is the best time for India to focus on building and improving its API manufacturing and export capabilities. According to Statistics, the Indian API market is projected to grow at a CAGR of 8.57% from 2020 to 2026. The Government of India has announced Rs. 6,940 Crore Production Linked Incentive (PLI) scheme to boost drug manufacturing in India. The scheme is mainly aimed at reducing imports through the promotion of domestic manufacturing of Active Pharmaceutical Ingredients (APIs) and Drug Intermediates.

Pharmaceutical Companies are continuously increasing outsourcing research activities to academic and private contract research organizations (CROs) to become and stay competitive in the market. After the COVID 19 pandemic, the pharmaceutical industry has gotten a new direction and is currently experiencing dynamic changes. That is why to reduce their R&D expenses, the companies to a significant extent are now relying on outsourcing service providers. Based on this, the opportunities available to India are Custom Chemical Synthesis or CCS, clinical trials, and contract manufacturing or CRAMS. However, the most scalable opportunity for Indian companies lies in contract manufacturing or CRAMS. This is because CRAMS supplies are linked to the success of a product post commercialization and can provide relatively stable revenues.

 

Annual Report

Arch PharmaLabs Annual Report 2021-22

Download

Arch PharmaLabs Annual Report 2020-21

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha